EMA Authorised: Fosavance (alendronic acid;colecalciferol) — Organon N.V.

View source ↗

Summary

EMA authorised Fosavance (alendronic acid and colecalciferol) by Organon N.V. for osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Fosavance (alendronic acid; colecalciferol)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Organon N.V.. Decision date: 12/02/2026